

Applicant: Michael A. Brownlee  
Serial No. 10/582,116  
Filed: June 26, 2007  
page 2 of 4

### Restriction Requirement

In the Office Action, the Examiner required restriction to one of the following three Groups of inventions:

- Group I, claim(s) 1, 3-4, 7, 18-19, 23-24, 29-31, 62, drawn to a method of inhibiting hyperglycemia-induced or free fatty acid-induced reactive oxygen formation comprising treating the cell with a pharmaceutically acceptable composition comprising GLP-1 (9-36);
- Group II, claim(s) 51-54, drawn to a method of inhibiting the development of disease due to diabetes, impaired glucose tolerance, metabolic syndrome, insulin resistance, ischemia/reperfusion injury, endotoxin injury, alcoholic liver disease and/or impaired glucose-stimulated insulin secretion; and
- Group III, claim(s) 67-70, drawn to an isolated and purified GLP-1 (9-36) consisting essentially of a sequence selected from the group consisting of SEQ ID NOs: 3-16.

In response to the restriction requirement, applicant hereby elects, without traverse, the invention identified by the Examiner as Group I, i.e. claim(s) 1, 3-4, 7, 18-19, 23-24, 29-31, 62, drawn to a method of inhibiting hyperglycemia-induced or free fatty acid-induced reactive oxygen formation comprising treating the cell with a pharmaceutically acceptable composition comprising GLP-1 (9-36).

### Election of Species Requirements

Applicants are required to elect a single species for any of Groups I-III for a single and specific peptide with its sequence fully identified and for Groups I-II for a single disease or biological event to be treated/inhibited.

Applicant: Michael A. Brownlee  
Serial No. 10/582,116  
Filed: June 26, 2007  
page 3 of 4

In response to the species elections, applicant hereby elects, without traverse, GLP-1 (9-36) (SEQ ID NO:1) and inhibiting hyperglycemia-induced reactive oxygen formation.

Claims 1, 3-4, 7, 18-19, 24, 29-31 and 62 are readable on the elections.

#### Supplemental Information Disclosure Statement

This Supplemental Information Disclosure Statement is being filed to supplement the Information Disclosure Statement filed on June 26, 2007 in connection with the subject application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant would like to direct the Examiner's attention to the references that are listed on enclosed Form PTO/SB/08A-B (2 pages). Copies of the non-patent literature documents are attached hereto. The references listed in the PCT International Search Report in connection with PCT/US2004/40852 were previously submitted on June 26, 2007 in connection with the subject application.


Applicant: Michael A. Brownlee  
Serial No. 10/582,116  
Filed: June 26, 2007  
page 4 of 4

No fee is deemed necessary in connection with the submission of this Communication. However, if any fee is required to maintain the pendency of the subject application, authorization is hereby given to withdraw the amount of any such fee from Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
New York, New York 10016  
(212) 336 8000

Dated: July 6, 2009  
New York, New York

By   
Alan D. Miller, Reg. No. 42,889